<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488472</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300001201</org_study_id>
    <nct_id>NCT03488472</nct_id>
  </id_info>
  <brief_title>Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain</brief_title>
  <acronym>RAD 1704</acronym>
  <official_title>A Pilot and Feasibility Trial to Determine the Rate of the Brain Relapse in Small Cell Lung Cancer (SCLC) Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS) Followed by Tumor Treating Fields (TTF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexell Hunter Boggs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective single arm trial designed to study the safety and effectiveness
      of a medical device, NovoTTF-200A, used with stereotactic radiosurgery (SRS) in subjects with
      brain metastases from small cell lung cancer (SCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are
      tuned to interfere with the division process of cancer cells. TTFields are delivered to the
      region of cancer using an investigational device, called the NovoTTF-200A system. The device
      is portable, light weighted, battery operated device designed to deliver TTFields to brain
      metastases from small cell lung cancer (SCLC).

      TTFields are a novel, non-invasive regional anti-mitotic treatment modality. Pre-clinical
      studies and clinical data in glioblastoma multiforme (GBM) have demonstrated a favorable
      safety profile and clinical superiority when treating the brain with TTFields. In addition,
      durable response have been demonstrated with 200kHz TTFields monotherapy for supratentorial
      tumors of the brain.

      The development of brain metastases is devastating for SCLC patients and their families.
      Treatment options in this setting are limited to SRS or WBRT or a combination thereof. Few
      clinicians treat SCLC brain metastases with SRS alone because intracranial recurrence is high
      due to the fact that the entire brain is not treated. WBRT treats the entire brain and
      improves intracranial control, but at the risk of neurocognitive complications. Thus, new
      therapeutic options are needed, particularly ones that allow for greater intracranial control
      while minimizing the risk of neurocognitive adverse events. As such, TTFields following SRS
      may allow for sufficient regional treatment of the brain to eliminate any remaining tumor
      cells following radiosurgery as well as micro-metastases that remain untreated, and
      ultimately prolong intracranial control. Due to the favorable safety profile seen in phase
      III recurrent and newly diagnosed glioblastoma trials and in which the patients reported
      improved neurocognitive and emotional functioning, NovoTTF-200A is not expected to have
      neuro-toxic effects seen with WBRT.

      Thus, the investigators hypothesize that the use of NovoTTF-200A applied to the brain
      following SRS for SCLC brain metastases will have cerebral control comparable to WBRT with
      less neurocognitive effects.

      The patient will undergo stereotactic radiosurgery (SRS). Radiosurgery is a single treatment
      and will be done as an outpatient procedure.

      Stereotactic Radiosurgery (SRS) will be followed by continuous TTFields treatment using the
      NovoTTF-200A. The patient will start using the NovoTTF-200A device within 7 days of SRS. The
      patient will be asked to return to the UAB Radiation Oncology Clinic. During the visit, the
      patient will be instructed, by the study doctor, research nurse, and/or Device Support
      Specialist (DDS) trained by NovoCure, on how to operate the device, replace depleted
      batteries, recharge them, and connect to an external power supply. All patients will be
      required to shave their head, so the transducer arrays can be placed. Patients will wear 4
      electronically insulated transducer arrays (sticky pads) on the top of the patient's head
      (based on the patient's tumor location) for the time the patient is using the device.

      After this visit, the patient will continue treatment at home where participants can maintain
      regular daily routine. The patient must use the device for at least 18 hours a day per day on
      average. Breaks are allowed for personal needs (e.g. showering/bathing, array exchange).
      Patients will be instructed to replace the Transducer arrays 2-3 times a week with help of a
      caregiver. Patients will be instructed to use the device for a minimum of 4 weeks from the
      time of initiation. The NovoTTF-200A device will be inspected, either by the study doctor,
      research nurse, or by a Novocure representative, on a monthly basis to assess the patient's
      compliance with treatment. Each course of using the device will consist of continuous
      NovoTTF-200A use for one month. Multiple courses will be offered as long as the patient's
      tumor(s) in the brain have not come back. If the patient's tumor(s) do come back, the patient
      will need to terminate use of NovoTTF-200A. If tumors do not return in the patient's brain,
      the patient will be able to stay on NovoTTF-200A for up to 1 year.

      Patients will be asked to visit the study doctor for follow-up care at several monthly
      intervals (1, 3, 6, 9, an 12 months after completion of stereotactic radiosurgery), or until
      the tumor(s) in the patient's brain return.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Distant Metastases</measure>
    <time_frame>From date of first SRS treatment to time of the 6 month follow-up MRI</time_frame>
    <description>Rate of distant CNS metastases/progression will be calculated as the total number of patients with such events divided by the total number of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From time of first SRS treatment to date of death, or censored as the last follow-up, whichever comes first, for up to 1 year.</time_frame>
    <description>Overall survival will be measured as time from first SRS treatment to date of death, or censored as the last follow-up, whichever comes first. Overall survival rates will be analyzed using the Kaplan-Meier (KM) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Recurrence</measure>
    <time_frame>From time of first SRS treatment to date of death, or censored as the last follow-up, whichever comes first, for up to 1 year.</time_frame>
    <description>Local recurrence will be defined as a measurable lesion deemed likely to be a brain metastases found within the treated area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant CNS Progression</measure>
    <time_frame>From time of first SRS treatment to date of death, or censored as the last follow-up, whichever comes first, for up to 1 year.</time_frame>
    <description>Distant CNS Progression is defined as development of new metastases outside the treated area.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NovoTTF-200A device + Stereotactic Radiosurgery (SRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-200A</intervention_name>
    <description>Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.</description>
    <arm_group_label>NovoTTF-200A device + Stereotactic Radiosurgery (SRS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery (SRS)</intervention_name>
    <description>SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.</description>
    <arm_group_label>NovoTTF-200A device + Stereotactic Radiosurgery (SRS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must have history of histologically confirmed small cell lung cancer.
             Brain biopsy is not required unless diagnosis is judged to be in doubt by the treating
             physician.

          -  Newly diagnosed brain metastases (metastases on post-contrast MRI obtained within six
             weeks of study entry) deemed to be amenable to SRS.

               -  Tumor size limited to largest volume &lt; 10 cc

               -  Longest diameter &lt; 3 cm

               -  Cumulative volume of all tumors â‰¤ 15 cc

          -  At least one measurable lesion per RANO-BM Criteria for brain metastasis.

          -  Prior prophylactic cranial irradiation (PCI) is allowed.

          -  Prior systemic therapy is allowed after diagnosis of brain metastases provided that
             restaging MRI shows measurable intracranial disease.

          -  Karnofsky Performance Status (KPS) of greater than or equal to 70.

          -  Age greater than or equal to 18 years.

          -  Life expectancy greater than 3 months.

          -  Must receive optimal therapy for extracranial disease and may continue on systemic
             therapy during TTF administration.

          -  Ability to operate the NovoTTF-200A device independently or with caregiver aid.

          -  Previous clinical trial enrollment is allowed.

          -  Subjects given written informed consent.

        Exclusion Criteria:

          -  History of prior brain metastases.

          -  Patients with significant edema leading to risk of brain herniation.

          -  History of prior whole brain radiotherapy (WBRT) other than prophylactic cranial
             radiation. Prophylactic cranial radiation with a maximum dose of 25 Gy delivered as 10
             fractions is allowed. WBRT in excess of 25 Gy (anything over 25 Gy) is not allowed.

          -  Diffuse Leptomeningeal metastases with radiographic involvement in the brain and/or
             spinal cord. This does not include local leptomeningeal involvement which is defined
             as leptomeningeal enhancement within direct contact of targetable metastases.

          -  Implantable electronic device in the brain.

          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other
             implanted electronic devices in the brain, or documented clinically significant
             arrhythmias.

          -  Evidence of increased intracranial pressure (midline shift &gt; 5mm, clinically
             significant papilledema, vomiting and nausea, or reduced level of consciousness).

          -  Known allergies to medical adhesives or hydrogel.

          -  Currently pregnant or breastfeeding.

          -  Concurrent brain-directed therapy.

          -  Insufficient recovery from all active toxicities of prior therapies.

          -  Women of childbearing potential who are not using an effective method of contraception
             are excluded. Women of childbearing potential must have a negative urine or serum
             pregnancy test within 24 hours prior to administration of SRS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drexell H Boggs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham (UAB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drexell H Boggs, MD</last_name>
    <phone>205-934-5670</phone>
    <email>dhboggs@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB), Hazelrig-Salter Radiation Oncology Center (HSROC)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Drexell Hunter Boggs</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

